Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MCLA-129 + befotertinib
- Development stage
- Phase 1
- Lead developer
- Merus
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
MCLA-129 + befotertinib is an investigational drug combination evaluated for the treatment of advanced non-small cell lung cancer (NSCLC) with EGFR-sensitive mutations. MCLA-129 is a bispecific monoclonal antibody that targets both the epidermal growth factor receptor (EGFR) and c-MET (hepatocyte growth factor receptor), inhibiting their signaling and enhancing antitumor immune responses (antibody-dependent cellular cytotoxicity/ADCC). Befotertinib is an orally available, third-generation, highly selective small molecule inhibitor of mutant EGFR (notably including T790M resistance mutation), which blocks EGFR-mediated tumor signaling. The combination aims to better suppress tumor growth by jointly targeting EGFR (including resistance mutations) and c-MET pathways, both of which commonly promote tumor proliferation and survival in NSCLC[1][4][5][6].
- Brand names
- Surmana
- Other names
- 1835667-63-4UNII-0XT2CPR891UNII0XT2CPR891UNII 0XT2CPR891bispecific anti-EGFR/c-Met antibody plus befotertinib
02
Targets
MET (Mesenchymal-epithelial transition factor receptor)EGFR T790M (Epidermal growth factor receptor T790M mutant)
Beyond the preview
Go deeper on MCLA-129 + befotertinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MCLA-129 + befotertinib.